SynthesisRadiation oncology (London, England)2024
Respiratory adverse effects in patients treated with immune checkpoint inhibitors in combination with radiotherapy: a systematic review and meta-analysis.
Synthesis in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic role of the baseline neutrophil‒eosinophil ratio in cancer patients: a meta-analysis and systematic review.World journal of surgical oncology · 2025Pooled it
- Salvage sleeve-pneumonectomy for a malignant bronchomediastinal fistula and the feasibility of a modified tritubeJournal of cardiothoracic surgery · 2026Article
- Whole Lung Irradiation in Ewing Sarcoma with Pulmonary Metastases: Critical Appraisal of Evolution, Evidence, and Future Pathways in Precision Oncology.Current treatment options in oncology · 2026Review
- Time-of-day radiotherapy alters radiation pneumonitis risk but not survival in lung cancer patients with interstitial lung disease.Therapeutic advances in medical oncology · 2026Article
- Risk factors, severity-related factors, and clinical outcomes of immune checkpoint inhibitor-associated pneumonitis in elderly patients with lung cancer.Frontiers in oncology · 2026Article
- Adapting federated radiomics models for radiation pneumonitis prediction in patients receiving thoracic radiotherapy with immunotherapy.Frontiers in immunology · 2026Article
- Article
- From local control to immune modulation: hypofractionated radiotherapy as a backbone for cancer immunotherapy.Frontiers in oncology · 2026Review
- The risk of symptomatic radiation pneumonitis in small cell lung cancer patients following sequential immunochemotherapy and radiotherapy: a multicenter retrospective cohort study.Radiation oncology (London, England) · 2025Article
- The impact of radiotherapy on the prognosis of metastatic clear cell renal cell carcinoma after surgery.Scientific reports · 2025Article
- A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy.Biomedicines · 2025Review
- Efficacy and Safety of Sintilimab in Combination With Anlotinib and Chemoradiotherapy as First-Line Treatment for Driver Gene-Negative Oligometastatic Non-small Cell Lung Cancer: A Real-World Cohort Study.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWe conducted a systematic review and meta-analysis to assess the risk of respiratory adverse effects in patients with solid tumors treated with immune checkpoint inhibitors (PD-1, PD-L1 and CTLA-4 inhibitors) in combination with radiation therapy.
methodsWe selected eligible studies through the following databases: PubMed, Embase, Cochrane Library, and Clinicaltrials ( https://clinicaltrials.gov/ ). The data was analyzed by using Rstudio.
resultsAmong 3737 studies, 26 clinical trials, including 2670 patients, were qualified for the meta-analysis. We evaluated the incidence rates of adverse respiratory events, including cough, pneumonia, upper respiratory tract infections, and others: grades 1-5 cough, 0.176 (95%CI: 0.113-0.274, I2 = 92.36%); grades 1-5 pneumonitis, 0.118 (95%CI: 0.067-0.198, I2 = 88.64%); grades 1-5 upper respiratory tract infection, 0.064 (95%CI: 0.049-0.080, I2 = 0.98%); grades 3-5 cough, 0.050 (95%CI: 0.012-0.204, I2 = 8.90%); grades 3-5 pneumonitis, 0.052 (95%CI: 0.031-0.078, I2 = 83.86%); grades 3-5 upper respiratory tract infection, 0.040 (95%CI: 0.007-0.249, I2 = 45.31%).
conclusionsOur meta-analysis demonstrated that ICI combined with radiotherapy for solid tumors can produce respiratory adverse effects. ICIs combination treatment, a tumor located in the chest, is more likely to cause adverse reactions, and SBRT treatment and synchronous treatment will bring less incidence of adverse reactions. This study provide insights for clinicians to balance the risks of radiotherapy in the course of treating oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.